Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Concomitant administration of certain fluoroquinolone antimicrobials and nonsteroidal antiinflammatory agents (NSAIDs) induces serious convulsion in humans. There are differences in convulsive activity among fluoroquinolones and in the potentiation of fluoroquinolone-induced convulsion among NSAIDs, but a comprehensive, quantitative comparison has not been carried out. This study evaluates the inhibitory effects of twelve fluoroquinolones (ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, norfloxacin, ofloxacin, pazufloxacin, prulifloxacin, sparfloxacin, and tosufloxacin) alone or in the presence of an NSAID (4-biphenylacetic acid, diclofenac sodium, loxoprofen, lornoxicam or zaltoprofen) on the GABA(A) receptor binding of [(3)H]muscimol in an in vitro study using mice synaptic plasma membrane. The rank order of inhibitory effects of the fluoroquinolones was prulifloxacin asymptotically equal to norfloxacin > ciprofloxacin > or = enoxacin > gatifloxacin > or = ofloxacin asymptotically equal to tosufloxacin asymptotically equal to lomefloxacin > levofloxacin > or = sparfloxacin > or = pazufloxacin asymptotically equal to fleroxacin. 4-Biphenylacetic acid most potently enhanced the inhibitory effects of the fluoroquinolones, while zaltoprofen, loxoprofen, lornoxicam and diclofenac had essentially no effect. The clinical risk of convulsion for each combination was estimated using a pharmacodynamic model based on receptor occupancy using the in vitro data set obtained and pharmacokinetic parameters in humans collected from the literature. The combinations of 4-biphenylacetic acid with prulifloxacin and enoxacin were concluded to be the most hazardous.
Kim
Jahye
J
Department of Medico-Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Ohtani
Hisakazu
H
Tsujimoto
Masayuki
M
Sawada
Yasufumi
Y
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002939:Ciprofloxacin / Q000009:adverse effects; D004008:Diclofenac; D004148:Dioxolanes; D004338:Drug Combinations; D004347:Drug Interactions; D015365:Enoxacin / Q000009:adverse effects; D016576:Fleroxacin / Q000009:adverse effects; D024841:Fluoroquinolones / Q000009:adverse effects*; D000077734:Gatifloxacin; D064704:Levofloxacin; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000009:adverse effects; D009643:Norfloxacin / Q000009:adverse effects / Q000494:pharmacology; D015242:Ofloxacin / Q000009:adverse effects / Q000494:pharmacology; D010078:Oxazines; D010648:Phenylacetates; D010879:Piperazines; D011963:Receptors, GABA-A / Q000032:analysis*; D012640:Seizures / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004148:Dioxolanes; D004338:Drug Combinations; D024841:Fluoroquinolones; D009287:Naphthyridines; D010078:Oxazines; D010648:Phenylacetates; D010879:Piperazines; D011963:Receptors, GABA-A; D004008:Diclofenac; D015365:Enoxacin; C078052:pazufloxacin; C012776:biphenylylacetic acid; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin; C055185:tosufloxacin; C074191:prulifloxacin; D000077734:Gatifloxacin; C053091:lomefloxacin; D009643:Norfloxacin; D016576:Fleroxacin; C061363:sparfloxacin